Trial reportClinical infectious diseases : an official publication of the Infectious Diseases Society of America2018
Seroefficacy of Vi Polysaccharide-Tetanus Toxoid Typhoid Conjugate Vaccine (Typbar TCV).
Trial report in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 3 syntheses or guidelines pooled it, 71 citations in OpenAlex.
- Typhoid conjugate vaccines for preventing typhoid fever (enteric fever).The Cochrane database of systematic reviews · 2025Pooled it
- Interventions to improve oral vaccine performance: a systematic review and meta-analysis.The Lancet. Infectious diseases · 2019Pooled it
- Vaccines for preventing typhoid fever.The Cochrane database of systematic reviews · 2018Pooled it
- Efficacy of typhoid conjugate vaccine in Nepal: final results of a phase 3, randomised, controlled trial.The Lancet. Global health · 2021Trial
- Phase 3 Efficacy Analysis of a Typhoid Conjugate Vaccine Trial in Nepal.The New England journal of medicine · 2019Trial
- Development and validation of immunological assays for preclinical evaluation of a novel bivalent typhoid conjugate vaccine.Human vaccines & immunotherapeutics · 2026Article
- Genetic heterogeneity in theMicrobial genomics · 2024Article
- Cost-effectiveness analysis of typhoid vaccination in Lao PDR.BMC public health · 2023Article
- Bacterial shedding and serologic responses following an outbreak of Salmonella Typhi in an endemic cohort.BMC infectious diseases · 2023Article
- Article
- Malnutrition and maternal vaccination against typhoid toxin.PLoS pathogens · 2022Article
- Bacterial AB toxins and host-microbe interactions.Advances in microbial physiology · 2022Review
- Mechanisms of typhoid toxin neutralization by antibodies targeting glycan receptor binding and nuclease subunits.iScience · 2021Article
- Article
- Vaccines and Senior Travellers.Frontiers in aging · 2021Review
- The molecular basis of extensively drug-resistant Salmonella Typhi isolates from pediatric septicemia patients.PloS one · 2021Article
- Epidemiological and Clinical Characteristics of International Travelers with Enteric Fever and Antibiotic Resistance Profiles of Their Isolates: a GeoSentinel Analysis.Antimicrobial agents and chemotherapy · 2020Article
- Typhoid Outbreaks, 1989-2018: Implications for Prevention and Control.The American journal of tropical medicine and hygiene · 2020Review
- The need & the issues related to new-generation typhoid conjugate vaccines in India.The Indian journal of medical research · 2020Review
- Cost-effectiveness of routine and campaign use of typhoid Vi-conjugate vaccine in Gavi-eligible countries: a modelling study.The Lancet. Infectious diseases · 2019Article
Corrections and comments
- Commented on by
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Salmonella Typhi is the major cause of enteric fever in lower-income countries. New conjugate vaccines show promise as public health interventions, but there are no efficacy data available from endemic areas. Methods: Data were obtained from a previously published phase 3 randomized controlled trial comparing Vi polysaccharide-tetanus toxoid conjugate vaccine (Vi-TT) with Vi polysaccharide vaccine (Vi-PS) in participants aged 2-45 years. An additional open-label arm administered Vi-TT to children aged 6-23 months. The proportion of participants with presumed clinical or subclinical infection ("seroincidence") was determined using mixture models and compared using relative risks (RRs). Results: Of 387 participants, 81 (21%) were classified as having presumed typhoid infection during the 2-year postvaccination period. Seroincidence was lower in participants randomized to Vi-TT rather than Vi-PS among those aged 2-45 years (RR, 0.372; 95% confidence interval [CI], .235-.588; P < .001) and those aged 2-15 years (RR, 0.424; 95% CI, .231-.778; P = .004). There was no difference in seroincidence for Vi-TT between those aged 2-45 years and those aged 6-23 months (RR, 1.073; 95% CI, .563-2.046; P = .83). Vaccine seroefficacy was 85% (95% CI, 80%-88%). Conclusion: This is the first field estimate of the seroefficacy of a Vi-TT vaccine and shows that Typbar TCV substantially reduces the number of serologically defined clinical or subclinical infections in infants, children, and adults. These results support the recent World Health Organization recommendations for deployment of typhoid conjugate vaccines in high-burden areas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.